Sell Your Addiction Treatment Center —
Confidentially

Addiction treatment centers typically sell for 4x to 7x adjusted EBITDA, with census stability, accreditation status, payer mix, and licensure compliance as the primary multiple drivers. Programs with consistent occupancy, CARF or Joint Commission accreditation, and commercial-heavy payer concentration command the higher end. Medicaid-heavy or census-volatile programs land lower regardless of top-line revenue — because buyers are acquiring the earnings, not the gross volume.

Accreditation carries both direct and indirect value. Directly, it supports payer relationships — some commercial payers require accreditation as a condition of contracting. Indirectly, it signals quality clinical operations and reduces regulatory diligence risk. The critical deal detail: accreditation does not transfer automatically with ownership. It must be re-evaluated or transferred as part of the transaction, with a timeline and documentation process that must be built into the closing structure.

Your clinical team and patients are not informed until a transaction is imminent and a transition plan is in place. In SUD treatment specifically, 42 CFR Part 2 governs what clinical information can be accessed during the sale process — patient records are not part of buyer diligence without specific consent procedures. For patients receiving MAT, transition planning prioritizes medication continuity, which BHBB treats as a planning obligation from the start.

The active buyer market is led by private equity-backed platforms building regional and national addiction treatment networks, typically within a defined level-of-care focus (IOP/PHP, residential, or integrated continuum). Larger behavioral health systems acquiring SUD service lines represent a second category. For smaller IOP or outpatient MAT programs, individual operators and regional acquirers represent a third segment. Buyer type shapes not only deal structure and timeline but post-close clinical integration expectations.

Census stability is the primary valuation variable in SUD programs — more so than in almost any other behavioral health sub-vertical. Consistent occupancy signals durable revenue, effective clinical operations, and a referral network generating reliable intake volume. Buyers examine census data across two to three years: seasonal patterns, average daily census by level of care, and intake source concentration. A program with volatile census, even at strong average revenue, will trade at a discount relative to a program with comparable revenue and consistent occupancy.

Methadone-based Opioid Treatment Program licensure — including SAMHSA certification, DEA registration, and state OTP licensure — is entity-specific and does not transfer with ownership. When ownership changes, each must be addressed as a closing condition with its own application timeline. Buprenorphine prescribing authority (DATA waiver / X-waiver) is tied to individual prescribers, not the entity. A transaction that treats MAT licensure as a post-close administrative task will close with a program that cannot legally operate as before. BHBB coordinates MAT licensure transfer workstreams from engagement.